THYPINONE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Nov 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
THYPINONE is a small-molecule injectable product approved by Abbott in 1976 with an unknown mechanism of action and indication profile. As a legacy NDA product, it represents a mature therapeutic agent in its late commercial lifecycle. The specific therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting contracting team and shift toward generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
THYPINONE currently has zero linked job openings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Professionals joining this product should expect focus on profitability defense, generic transition planning, and operational efficiency rather than growth initiatives.
Brand ManagerProduct Manager
Worked on THYPINONE at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.